The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Intussusception Risk after Rotavirus Vaccination in U.S. Infants
Open accessAbstract
BACKGROUND: International postlicensure studies have identified an increased risk of intussusception after vaccination with the second-generation rotavirus vaccines RotaTeq (RV5, a pentavalent vaccine) and Rotarix (RV1, a monovalent vaccine). We studied this association among infants in the United States. METHODS: The study included data from infants 5.0 to 36.9 weeks of age who were enrolled in three U.S. health plans that participate in the Mini-Sentinel program sponsored by the Food and Drug Administration. Potential cases of intussusception and vaccine exposures from 2004 through mid-2011 were identified through procedural and diagnostic codes. Medical records were reviewed to confirm the occurrence of intussusception and the status with respect to rotavirus vaccination. The primary analysis used a self-controlled risk-interval design that included only vaccinated children. The secondary analysis used a cohort design that included exposed and unexposed person-time. RESULTS: The analyses included 507,874 first doses and 1,277,556 total doses of RV5 and 53,638 first doses and 103,098 total doses of RV1. The statistical power for the analysis of RV1 was lower than that for the analysis of RV5. The number of excess cases of intussusception per 100,000 recipients of the first dose of RV5 was significantly elevated, both in the primary analysis (attributable risk, 1.1 [95% confidence interval, 0.3 to 2.7] for the 7-day risk window and 1.5 [95% CI, 0.2 to 3.2] for the 21-day risk window) and in the secondary analysis (attributable risk, 1.2 [95% CI, 0.2 to 3.2] for the 21-day risk window). No significant increase in risk was seen after dose 2 or 3. The results with respect to the primary analysis of RV1 were not significant, but the secondary analysis showed a significant risk after dose 2. CONCLUSIONS: RV5 was associated with approximately 1.5 (95% CI, 0.2 to 3.2) excess cases of intussusception per 100,000 recipients of the first dose. The secondary analysis of RV1 suggested a potential risk, although the study of RV1 was underpowered. These risks must be considered in light of the demonstrated benefits of rotavirus vaccination. (Funded by the Food and Drug Administration.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kulldorff, M. (1997) · Communications in Statistics - Theory and Methods · doi:10.1080/03610929708831995 · Cited by 3,939
Self-citationIntussusception among Infants Given an Oral Rotavirus Vaccine
Murphy, T. V., Gargiullo, P. M., Massoudi, M. S., Nelson, D. B., Jumaan, A. O., Okoro, C. A., Zanardi, L. R., Setia, S., Fair, E., LeBaron, C. W., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200102223440804 · Cited by 973
Vaccines for preventing rotavirus diarrhoea: vaccines in use
Soares‐Weiser, K., MacLehose, H. G., Bergman, H., Ben‐Aharon, I., Nagpal, S., Goldberg, E., Pitan, F., & Cunliffe, N. A. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008521.pub3 · Cited by 381
The U.S. Food and Drug Administration's Mini‐Sentinel program: status and direction
Platt, R., Carnahan, R. M., Brown, J. S., Chrischilles, E., Curtis, L. H., Hennessy, S., Nelson, J. C., Racoosin, J. A., Robb, M., Schneeweiss, S., et al. (2012) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.2343 · Cited by 287
Self-citationDesign considerations, architecture, and use of the Mini‐Sentinel distributed data system
Curtis, L. H., Weiner, M. G., Boudreau, D. M., Cooper, W. O., Daniel, G. W., Nair, V. P., Raebel, M. A., Beaulieu, N. U., Rosofsky, R., Woodworth, T. S., et al. (2012) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.2336 · Cited by 224
Vu, H. T. T., Yoshida, L. M., Suzuki, M., Nguyen, H. A. T., Nguyen, C. D. L., Nguyen, A. T. T., Oishi, K., Yamamoto, T., Watanabe, K., Vu, T. D., et al. (2011) · Pediatric Infectious Disease Journal · doi:10.1097/inf.0b013e3181f111a2 · Cited by 208
Carlin, J. B., Macartney, K. K., Lee, K. J., Quinn, H. E., Buttery, J., Lopert, R., Bines, J., & McIntyre, P. B. (2013) · Clinical Infectious Diseases · doi:10.1093/cid/cit520 · Cited by 191
Design of a National Distributed Health Data Network
Maro, J. C., Platt, R., Holmes, J. H., Strom, B. L., Hennessy, S., Lazarus, R., & Brown, J. S. (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-151-5-200909010-00139 · Cited by 165
Self-citationTate, J. E., Mutuc, J. D., Panozzo, C. A., Payne, D. C., Cortese, M. M., Cortes, J. E., Yen, C., Esposito, D. H., Lopman, B. A., Patel, M. M., et al. (2010) · The Pediatric Infectious Disease Journal · doi:10.1097/inf.0b013e3181ffe3eb · Cited by 130
Glanz, J. M., McClure, D. L., XU, S., Hambidge, S. J., LEE, M., KOLCZAK, M. S., KLEINMAN, K. P., Mullooly, J. P., & France, E. K. (2006) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2005.11.012 · Cited by 117
Quintanar-Solares, M., Yen, C., Richardson, V., Esparza‐Aguilar, M., Parashar, U. D., & Patel, M. M. (2010) · The Pediatric Infectious Disease Journal · doi:10.1097/inf.0b013e3181fefb32 · Cited by 109
Nguyen, M., Ball, R., Midthun, K., & Lieu, T. A. (2012) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.2323 · Cited by 103
Self-citationDoes Influenza Vaccination Exacerbate Asthma?: Analysis of a Large Cohort of Children With Asthma
Kramarz, P. (2000) · Archives of Family Medicine · doi:10.1001/archfami.9.7.617 · Cited by 102
Effect of Rotavirus Vaccine on Diarrhea Mortality in Different Socioeconomic Regions of Mexico
Gastañaduy, P. A., Sánchez-Uribe, E., Esparza‐Aguilar, M., Desai, R., Parashar, U. D., Patel, M. M., & Richardson, V. (2013) · PEDIATRICS · doi:10.1542/peds.2012-2797 · Cited by 64
Comparison of epidemiologic methods for active surveillance of vaccine safety
McClure, D. L., Glanz, J. M., Xu, S., Hambidge, S. J., Mullooly, J. P., & Baggs, J. M. (2008) · Vaccine · doi:10.1016/j.vaccine.2008.03.074 · Cited by 44
Klein, N. P., Hansen, J. R., Lewis, E. M., Lyon, L. L., Nguyen, B., BLACK, S. B., Weston, W. M., Wu, S., Li, P., Howe, B., et al. (2010) · The Pediatric Infectious Disease Journal · doi:10.1097/inf.0b013e3181d581f9 · Cited by 39
An Outbreak of Mycobacterium mucogenicum Bacteremia in Pediatric Hematology-oncology Patients
Shachor‐Meyouhas, Y., Sprecher, H., Eluk, O., Ben‐Barak, A., & Kassis, I. (2010) · The Pediatric Infectious Disease Journal · doi:10.1097/inf.0b013e3181ee31d7 · Cited by 38
Cited by
Liang, J. L., Tiwari, T., Moro, P., Messonnier, N. E., Reingold, A., Sawyer, M., & Clark, T. A. (2018) · MMWR. Recommendations and Reports · doi:10.15585/mmwr.rr6702a1 · Cited by 457
Bányai, K., Estes, M. K., Martella, V., & Parashar, U. D. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31128-0 · Cited by 445
Vaccines for preventing rotavirus diarrhoea: vaccines in use
Soares‐Weiser, K., MacLehose, H. G., Bergman, H., Ben‐Aharon, I., Nagpal, S., Goldberg, E., Pitan, F., & Cunliffe, N. A. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008521.pub3 · Cited by 381
Desselberger, U. (2014) · Virus Research · doi:10.1016/j.virusres.2014.06.016 · Cited by 376
Big data hurdles in precision medicine and precision public health
Prosperi, M., Min, J. S., Bian, J., & Modave, F. (2018) · BMC Medical Informatics and Decision Making · doi:10.1186/s12911-018-0719-2 · Cited by 200
“This will allow researchers to reach populations in vast numbers and allow implementation of novel study designs, such as examining rare adverse effects of a drug which randomized clinical trials cannot be sufficiently powered to detect [112].”
Background
Metadata
- Authors
- Yih, W. K., Lieu, T. A., Kulldorff, M., Martin, D., McMahill-Walraven, C. N., Platt, R., Selvam, N., Selvan, M., Lee, G. M., & Nguyen, M.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2014-02-06
- Volume
- 370
- Issue
- 6
- Pages
- 503-512
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2127264038
- Cited by
- 318
- References
- 17
- FWCI
- 41.22
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.